Recent studies have centered on the intersection of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and dopamine communication. While GIP activators are increasingly employed for addressing type 2 diabetes mellitus, their potential impacts on reinforcement circuits, specifically